News

Filter

Report: Latuda has greatest commercial potential among new agents entering the bipolar drug market

Report: Latuda has greatest commercial potential among new agents entering the bipolar drug market

15-10-2013

Dainippon Sumitomo Pharma/Sunovion/Takeda Pharmaceutical’s atypical antipsychotic Latuda (lurasidone)…

Dainippon Sumitomo PharmaGlobalLatudaMarkets & MarketingNeurologicalPharmaceuticalTakeda Pharmaceuticals

Takeda gains first European approval for lurasidone

14-08-2013

Japan's largest drugmaker Takeda Pharma (TYO: 4502) says it has been granted approval by Switzerland's…

Dainippon Sumitomo PharmaEuropeLatudalurasidoneNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticals

Back to top